- Home
- PRAX vs AXTA Comparison
PRAX vs AXTA Comparison
Compare PRAX & AXTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRAX | AXTA |
|---|---|---|
| Founded | 2015 | 1910 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Paints/Coatings |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.2B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | PRAX | AXTA |
|---|---|---|
| Price | $312.37 | $33.41 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 13 | 14 |
| Target Price | ★ $397.85 | $36.36 |
| AVG Volume (30 Days) | 623.7K | ★ 3.6M |
| Earning Date | 02-27-2026 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 40.67 |
| EPS | N/A | ★ 2.09 |
| Revenue | $7,463,000.00 | ★ $5,166,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $14,827.76 | $2.01 |
| P/E Ratio | ★ N/A | $15.91 |
| Revenue Growth | ★ 364.98 | N/A |
| 52 Week Low | $26.70 | $26.28 |
| 52 Week High | $326.91 | $38.37 |
Technical Indicators
Market Signals| Indicator | PRAX | AXTA |
|---|---|---|
| Relative Strength Index (RSI) | 63.20 | 65.65 |
| Support Level | $266.93 | $32.76 |
| Resistance Level | $326.91 | $33.61 |
| Average True Range (ATR) | 17.87 | 0.62 |
| MACD | 0.13 | -0.05 |
| Stochastic Oscillator | 75.94 | 72.95 |
Price Performance
Historical ComparisonAbout PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About AXTA Axalta Coating Systems Ltd.
Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific, and Latin America.